Kaskela Law LLC is investigating potential legal claims on behalf of stockholders of Kalaris Therapeutics, Inc. (NASDAQ: KLRS), formerly known as AlloVir, Inc. (ALVR), who received their shares of Kalaris Therapeutics, Inc. (NASDAQ: KLRS) (“Kalaris”) stock in connection with Kalaris’ March 2025 merger with AlloVir.
Since the time the merger closed in March 2025, shares of Kalaris’ stock have declined in value from over $9.00 per share to a current trading price of less than $5.00 per share, a decline of nearly 45% in value.
Former AlloVir (ALVR) shareholders whose ALVR shares were exchanged for Kalaris (KLRS) shares in March 2025 are encouraged to contact Kaskela Law (D. Seamus Kaskela, Esq. or Adrienne Bell, Esq.) for additional information about this investigation and their legal rights and options at (484) 229 – 0750, by email at [email protected], or by completing the form on this page.